Blood test could spare some kidney cancer patients from unnecessary drugs
NCT ID NCT06005818
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study is for people with high-risk kidney cancer that has been surgically removed. It uses a blood test to look for tiny bits of cancer DNA (molecular residual disease). If no DNA is found, patients skip standard immunotherapy (pembrolizumab); if DNA is found, they receive it. The goal is to see if this personalized approach improves how long patients stay cancer-free and overall survival.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Pembrolizumab (a drug that helps the immune system fight cancer)
What this could lead to
If successful, this could show that using a blood test to detect leftover cancer DNA helps decide who needs further treatment, potentially sparing some patients from unnecessary therapy.
What could go wrong
This is a small, early-phase (Phase 2) trial with only 100 participants. The approach may not improve survival or could miss some cancers. Pembrolizumab can cause immune-related side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RENAL CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University of Alabama at Birmingham
RECRUITINGBirmingham, Alabama, 35233, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••